The unregulated peptide market has two tiers. 'Gray market' sources, often sold for 'research only,' typically provide 99% purity data sheets, confirming the substance's identity despite contamination risks. 'Black market' sources offer no verification, meaning the vial's contents are completely unknown and far riskier.

Suppliers label products 'for research use only' to legally ship them for non-human applications. This allows consumers, framed as amateur scientists, to purchase substances for personal use, bypassing FDA approval for human consumption and creating a thriving gray market.

Up to 25% of people experience a euphoric response when taking opioids, a key driver of addiction. The risk is highest for the subset of this group (about 5-6% of the total population) who also have predisposed addictive tendencies. This shows how a prescribed medication can inadvertently lead to addiction in a vulnerable population segment.

While traditional opioids target the brain's MOP receptor for pain relief (causing euphoria), the NOP receptor can enhance pain relief while suppressing MOP's addictive side effects. Tris Pharma's new drug is a first-in-class molecule that equally targets both receptors, aiming for effective pain management without the addictive high.

Beyond the risk of addiction, the widespread prescription of opioids creates other major problems. These include gastrointestinal side effects like constipation and nausea, as well as the societal risk of leftover pills being stolen, sold, or accidentally used by children. This broader problem statement fortifies the argument for safer alternatives like Nav1.8 inhibitors.

The demand for unregulated peptides isn't just from niche biohackers; it's also from older individuals seeking relief for conditions like chronic joint pain where traditional medicine offers few effective solutions. This highlights a significant unmet need driving patients to experimental substances.

Most opioid-related deaths are not from an overdose of a single, pure substance. They result from user ignorance about two key factors: lethal contaminants like fentanyl mixed into the supply, and the exponentially increased risk of combining opioids with other sedatives like alcohol or benzodiazepines.

The drug crisis may be perpetuated by a system that benefits from its existence, including pharmaceutical companies, bureaucracies, and consultants. The proposed solution of providing more prescribed drugs is framed as ironically profiting the same industry that helped cause the opioid crisis, creating a perverse incentive against recovery.

To get FDA approval, new opioids must undergo Human Abuse Potential (HAP) studies. In these counter-intuitive trials, the goal is to lose. The drug is tested on recreational opioid users to measure its 'liking' score. Success is defined by demonstrating the new drug is significantly less preferable than existing abusable opioids like Oxycodone.